| Metric | Value ($ M) | vs Q1 FY26 |
|---|---|---|
| Revenue | 8.86 | 35.1% |
| Total Income | 8.86 | 35.1% |
| Expenditure | 131.15 | 13.9% |
| PBT | — | |
| Net Profit | -112.45 | 14.1% |
| OPM | — | |
| NPM | — | |
| EPS | -1.22 | 9.9% |
IDEAYA Biosciences Reports Q2 2026 Financial Results and Provides Business Update
04 Aug 2026 · 4 Aug, 3:38 pm
Summary
IDEAYA Biosciences reported its financial results for the second quarter ended June 30, 2026, alongside a business update. The company highlighted significant progress in its clinical pipeline, including the OPTIMUM-02 trial meeting its primary endpoint and an ongoing NDA submission for darovasertib. Collaboration revenue increased to $8.9 million from $6.6 million in the prior quarter, while the net loss widened to $112.5 million from $98.5 million. IDEAYA also announced a collaboration with Roche and maintained its cash runway guidance into 2030, supported by approximately $1.24 billion in cash reserves.
Key Highlights
- 1
The registrational OPTIMUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint, with an NDA filing underway.
- 2
Updated data from Phase 2 OptimUM-01 and OptimUM-09 trials, as well as from the Hengrui-sponsored Phase 1 trial of IDE849, are planned for presentation at ESMO.
- 3
A clinical collaboration with Roche was announced to evaluate IDE892 in combination with RG6505 in MTAP-deleted, RAS-mutant pancreatic cancer, targeting a Phase 1 trial initiation in H2 2026.
- 4
IDEAYA plans to host an R&D Day in Q4 2026 focused on MTAP/CDKN2A, KRAS, and pancreatic cancer.
- 5
As of June 30, 2026, the Company had approximately $1.24 billion in cash, cash equivalents, and marketable securities, with cash runway guidance into 2030 unchanged.
- 6
Collaboration revenue for the three months ended June 30, 2026, totaled $8.9 million, an increase from $6.6 million in the prior quarter.
- 7
Net loss for the three months ended June 30, 2026, was $112.5 million, compared to a net loss of $98.5 million for the prior quarter.
Management Comments
Yujiro S. Hata
This quarter marked another successful step forward in our mission to deliver new, potentially best-in-class precision therapies for people with cancer. We presented the positive topline results at ASCO from our registrational Phase 2/3 OptimUM-02 trial in HLA*A2:01-negative metastatic uveal melanoma while continuing to advance our NDA submission and pre-commercial activities to support a possible commercial launch. Additionally, our clinical pipeline is poised to deliver several key updates throughout the remainder of 2026, including updated data from IDE849, our DLL3 TOP1 ADC, in SCLC and NEC and clinical progress in MTAP-deleted cancers with IDE892, our PRMT5 inhibitor, as both a monotherapy and in combination with IDE397, our proprietary MAT2A inhibitor, and RG6505, Roche’s Phase 1 pan-RAS inhibitor in NSCLC and PDAC, respectively. With over $1.2 billion in cash following our successful financing in June, IDEAYA is well-positioned to continue advancing our precision medicine pipeline through multiple key data updates.
Informational and educational content only. Not investment advice.